Compounds > moguisteine
Page last updated: 2024-11-06

moguisteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID65935
CHEMBL ID146980
SCHEMBL ID358534
MeSH IDM0232782

Synonyms (57)

Synonym
AC-4727
AKOS015843415
bbr-2173
moguisteine
OPREA1_020741
ethyl (+-)-2-((o-methoxyphenoxy)methyl)-beta-oxo-3-thiazolidinepropionate
moguisteina [inn-spanish]
r,s(+-)-2-(2-methoxyphenoxy)-methyl-3-ethoxycarbonylacetyl-1,3-thiazolidine
moguisteinum [inn-latin]
moguisteine [inn]
ethyl 2-((2-methoxyphenoxy)methyl)-beta-oxo-3-thiazolidinepropanoate (+-)-
3-thiazolidinepropanoic acid, 2-((2-methoxyphenoxy)methyl)-beta-oxo-, ethyl ester, (+-)-
nsc-759829
CHEMBL146980
119637-67-1
121GE004
ethyl 3-[2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl]-3-oxopropanoate
FT-0656011
A804330
bbr2173;ethyl 3-[2-[(2-methoxyphenoxy)methyl]thiazolidin-3-yl]-3-oxo-propanoate
HMS3264I22
nsc 759829
moguisteinum
6y556547yy ,
unii-6y556547yy
moguisteina
pharmakon1600-01502311
nsc759829
BCP9000958
S3104
CCG-213816
HY-B0505
smr002529585
MLS006010420
KS-5161
ethyl (+/-)-2-((o-methoxyphenoxy)methyl)-.beta.-oxo-3-thiazolidinepropionate
moguisteine [mart.]
SCHEMBL358534
ethyl 3-(2-((2-methoxyphenoxy)methyl)thiazolidin-3-yl)-3-oxopropanoate
AB01563359_02
AB01563359_01
J-004167
SR-01000944248-1
sr-01000944248
ethyl 3-{2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl}-3-oxopropanoate
HMS3651H22
ethyl 3-[2-(2-methoxyphenoxymethyl)-1,3-thiazolidin-3-yl]-3-oxopropanoate
SW219622-1
M3305
BCP05219
2-(2-methoxyphenoxy)methyl-1,3-thiazolidine
mfcd00866839
BRD-A87673115-001-01-7
3-thiazolidinepropanoic acid, 2-[(2-methoxyphenoxy)methyl]-beta-oxo-, ethyl ester
Q27265705
C71662
DTXSID00869634

Research Excerpts

Overview

Moguisteine is a non-narcotic peripheral antitussive drug. It has been effective and well-tolerated in clinical studies.

ExcerptReferenceRelevance
"Moguisteine is a non-narcotic peripheral antitussive drug that has been effective and well-tolerated in clinical studies. "( Single- and multiple-dose pharmacokinetics of the peripheral non-narcotic antitussive moguisteine in healthy Chinese volunteers.
Feng, P; Gou, ZP; Wang, Y; Xiang, J; Zheng, L, 2019)		2.18
"Moguisteine is a new non-narcotic antitussive agent. "( Direct HPLC separation of enantiomers of main moguisteine metabolite: comparison of different stationary phases.
Bernareggi, A; Castoldi, D; Oggioni, A, 1994)		1.99
"Moguisteine is a novel peripheral non-narcotic antitussive agent. "( Assay of moguisteine metabolites in human plasma and urine: conventional and chiral high-performance liquid chromatographic methods.
Bernareggi, A; Castoldi, D; Di Giovine, S; Oggioni, A; Ratti, E; Renoldi, MI, 1994)		2.15

Toxicity

ExcerptReferenceRelevance
" Adverse events were observed in two patients on moguisteine, three on codeine 15 mg, and five on codeine 30 mg."( The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough.
Barnabè, R; Berni, F; Clini, V; Pirrelli, M; Pisani Ceretti, A; Robuschi, M; Rossi, M; Sestini, P; Tana, F; Vaghi, A, 1995)		0.84
" No serious adverse events were reported."( Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases.
Allegra, L; Aversa, C; Cazzola, M; Clini, V; Dal Negro, R; Maiorano, V; Tana, F, 1993)		0.55

Pharmacokinetics

Moguisteine was detectable at the shortest time points after moguistein administration. The time to achieve peak concentration was 0.

ExcerptReferenceRelevance
" Thus, for later moguisteine pharmacokinetic evaluations the investigation of the plasma concentration-time curve and the urinary excretion of the sole racemic M1 through non-stereospecific analytical methods may suffice in most cases."( Stereoselective pharmacokinetics of moguisteine metabolites in healthy subjects.
Bernareggi, A; Carlesi, RM; Castoldi, D; Ceserani, R; Crema, A; Ratti, D; Ratti, E; Renoldi, MI; Tognella, S, )		0.75
" The method was successfully applied to the pharmacokinetic study after oral administration of single-dose and multiple-dose of moguisteine tablets in healthy Chinese subjects."( Determination of the active metabolite of moguisteine in human plasma and urine by LC-ESI-MS method and its application in pharmacokinetic study.
Bu, F; Guo, R; Liu, X; Song, H; Teng, Y; Wang, B; Wei, C; Yuan, G; Zhang, R; Zhao, W, 2012)		0.85

Dosage Studied

ExcerptRelevanceReference
" After repeated dosing (12-15 days), moguisteine did not induce tolerance in either guinea-pigs or dogs."( Moguisteine: a novel peripheral non-narcotic antitussive drug.
Borghi, A; Ceserani, R; Dalla Rosa, C; Gallico, L; Tognella, S, 1994)		2
" Safety of the dosing schedules was assessed based on physical examination, recording of adverse events, 12-lead electrocardiography, and laboratory tests."( Single- and multiple-dose pharmacokinetics of the peripheral non-narcotic antitussive moguisteine in healthy Chinese volunteers.
Feng, P; Gou, ZP; Wang, Y; Xiang, J; Zheng, L, 2019)		0.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID74202Antitussive activity by inhibition of irritant citric acid aerosol-induced coughing in guinea pig upon oral administration.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
N-acyl-2-substituted-1,3-thiazolidines, a new class of non-narcotic antitussive agents: studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-beta-oxothiazolidine-3-propanoate.
AID74204Inhibition of irritant electrically-induced coughing in guinea pig trachea following p.o. administration.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
N-acyl-2-substituted-1,3-thiazolidines, a new class of non-narcotic antitussive agents: studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-beta-oxothiazolidine-3-propanoate.
AID116880Acute toxicity was determined in mice upon peroral administration1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
N-acyl-2-substituted-1,3-thiazolidines, a new class of non-narcotic antitussive agents: studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-beta-oxothiazolidine-3-propanoate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (69.57)18.2507
2000's4 (17.39)29.6817
2010's3 (13.04)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.88 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.50%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
citric acid, anhydrous
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.		2.6830tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		1.9910sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
phosphoric acid
phosphoric acid: concise etchant is 37% H3PO4. phosphoric acid : A phosphorus oxoacid that consists of one oxo and three hydroxy groups joined covalently to a central phosphorus atom.		1.9810phosphoric acidsalgal metabolite;
fertilizer;
human metabolite;
NMR chemical shift reference compound;
solvent
dipropizine
[no description available]		2.4220piperazines
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		2.4120monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		7.4120pyridines
procaterol
Procaterol: A long-acting beta-2-adrenergic receptor agonist.		2.0510quinolines
methacholine chloride
Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)		2.0510quaternary ammonium salt
methylene chloride
Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.		1.9810chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
diphenhydramine hydrochloride
Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.		7.84223hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
thiazoles
[no description available]		6.181821,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		7.88233thiazolidine
substance p
[no description available]		2.0810peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
naringin
[no description available]		2.0810(2S)-flavan-4-one;
4'-hydroxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
neohesperidoside		anti-inflammatory agent;
antineoplastic agent;
metabolite
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		1.9810cyclodextrin
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		3.5180capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
codeine
[no description available]		10.8871morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
dihydrocodeine
dihydrocodeine: RN refers to parent cpd(5alpha,6alpha)-isomer		2.4120morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		2.420morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		3.1410morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
codeine phosphate
[no description available]		1.9810
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		3.51206-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		6.9910dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
ConditionIndicatedRelationship StrengthStudiesTrials
Neurogenic Inflammation
Inflammation caused by an injurious stimulus of peripheral neurons and resulting in release of neuropeptides which affect vascular permeability and help initiate proinflammatory and immune reactions at the site of injury.		02.0810
Cough
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.		06.81132
Chronic Illness
[description not available]		05.5532
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		05.5532
Obstructive Lung Diseases
[description not available]		03.3711
Cancer of Lung
[description not available]		03.3711
Alveolitis, Fibrosing
[description not available]		03.3711
Lung Diseases, Obstructive
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.		03.3711
Lung Neoplasms
Tumors or cancer of the LUNG.		03.3711
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.		03.3711
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.3920
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		01.9810
Delayed Effects, Prenatal Exposure
[description not available]		01.9810
Weight Gain
Increase in BODY WEIGHT over existing weight.		01.9810
Respiratory Tract Diseases
Diseases involving the RESPIRATORY SYSTEM.		03.3711
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.6930
Innate Inflammatory Response
[description not available]		01.9910
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		06.9910
Bronchial Hyperreactivity
Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.		01.9910
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9910
Allergic Reaction
[description not available]		01.9910
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		01.9910